{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Risk&page=2", "query": { "condition": "Cancer Risk", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Risk&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:45:02.656Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01392183", "title": "Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Quality of Life Assessment", "type": "BEHAVIORAL" }, { "name": "Benadryl", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2012-10-24", "completion_date": "2019-09-08", "has_results": true, "last_update_posted_date": "2021-09-20", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01392183" }, { "nct_id": "NCT04023331", "title": "67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Relapsed Neuroblastoma", "Refractory Neuroblastoma" ], "interventions": [ { "name": "67Cu-SARTATE", "type": "DRUG" }, { "name": "64Cu-SARTATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clarity Pharmaceuticals Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2020-08-18", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 8, "location_summary": "Phoenix, Arizona • St Louis, Missouri • New York, New York + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04023331" }, { "nct_id": "NCT04634877", "title": "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiotherapy (EBRT)", "type": "RADIATION" }, { "name": "Cisplatin (as radiosensitizer)", "type": "DRUG" }, { "name": "Brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 990, "start_date": "2021-01-10", "completion_date": "2026-09-15", "has_results": false, "last_update_posted_date": "2025-06-09", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634877" }, { "nct_id": "NCT02280356", "title": "Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "external beam radiation therapy", "type": "RADIATION" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "RADIATION", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-10-28", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02280356" }, { "nct_id": "NCT06923527", "title": "Circulating Tumor DNA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ER+ Breast Cancer" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-09-30", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06923527" }, { "nct_id": "NCT00492505", "title": "Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "sorafenib tosylate", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "San Diego Pacific Oncology & Hematology Associates", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2007-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 1, "location_summary": "Encinitas, California", "locations": [ { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492505" }, { "nct_id": "NCT00625066", "title": "Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Precancerous Condition" ], "interventions": [ { "name": "biologic sample preservation procedure", "type": "OTHER" }, { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "survey administration", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "evaluation of cancer risk factors", "type": "PROCEDURE" }, { "name": "screening colonoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 8108, "start_date": "2003-01-01", "completion_date": "2025-11-30", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 4, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625066" }, { "nct_id": "NCT02169505", "title": "Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2015-05-22", "completion_date": "2017-08-14", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02169505" }, { "nct_id": "NCT01853345", "title": "iCAT for Recurrent/Refractory/HR Solid Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pediatric Solid Tumor", "Sarcoma", "Neuroblastoma", "Wilms Tumor" ], "interventions": [], "intervention_types": [], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 101, "start_date": "2012-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-02-10", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 5, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01853345" }, { "nct_id": "NCT00003972", "title": "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 280, "start_date": "1998-07", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-05-22T09:45:02.656Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003972" } ] }